Sector News

Zoetis knocks off 165 NJ jobs in Ackman-forced cost squeeze

June 19, 2015
Life sciences
Last month, under activist investor pressure, animal health leader Zoetis announced some cost-cutting blueprints it said would save it $300 million by 2017. And now, 165 New Jersey workers are hitting the road as part of that plan.
 
The company has filed a WARN notice with the state’s department of labor, and the employees–based in Florham Park, where the drugmaker is headquartered–will be out the door between this August and the end of next year, company spokeswoman Elinore White told FiercePharma. The departing staffers will receive severance, according to the WARN letter–provided they sign release agreements.
 
Those 165 positions are just a fraction of the total number Zoetis said in May it expects to shed, citing a workforce reduction of about 25%–or 2,500 jobs. Manufacturing, in particular, has been hit hard, with the company announcing it intends to close 10 unnamed sites as part of the cost squeeze.
 
Zoetis can thank rebel investor Pershing Square Capital Management–run by Bill Ackman–for putting it through the ringer. Ackman first picked up a stake in the Pfizer spinoff last fall, when some speculated he could use it as a backup buy if he and partner Valeant lost out on their hostile takeover try for Allergan.
 
While that still hasn’t happened, Pershing Square has been ramping up the pressure on Zoetis, in February winning a seat on the company’s board of directors.
 
In the meantime, though, other buyout rumors have been floating around, and if any of them eventually come true, more layoffs could be on the way. Industry watchers say Zoetis could make an attractive target for Bayer, which has long been looking to beef up its animal health business–and which will have some extra cash once it goes through with plans to divest its plastics division.
 
By Carly Helfand
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach